FDA Finalizes Guidance on Co-Crystals in NDAs and ANDAs Post author:Sam Post published:February 14, 2018 Post category:Drug Industry Daily The FDA finalized new guidance establishing co-crystals as a drug product intermediate. Source: Drug Industry Daily You Might Also Like J&J Finalizes Executive Committee Ahead of Splitting Pharma, Consumer Operations December 12, 2021 CDER Offers Guidance on Developing Drugs for Celiac Disease April 18, 2022 EMA Safety Committee Recommends Stopping Infusions of HES Solutions, Launches Review of Janus Kinase Inhibitors February 11, 2022
EMA Safety Committee Recommends Stopping Infusions of HES Solutions, Launches Review of Janus Kinase Inhibitors February 11, 2022